25,610 Shares in Johnson & Johnson (NYSE:JNJ) Purchased by Golden State Equity Partners

Golden State Equity Partners acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 25,610 shares of the company’s stock, valued at approximately $3,970,000. Johnson & Johnson makes up about 2.1% of Golden State Equity Partners’ investment portfolio, making the stock its 5th largest position.

A number of other institutional investors have also added to or reduced their stakes in the stock. GW&K Investment Management LLC bought a new position in Johnson & Johnson in the 4th quarter worth about $35,000. Dark Forest Capital Management LP lifted its holdings in Johnson & Johnson by 1,044.4% in the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after buying an additional 188 shares during the period. Atlantic Private Wealth LLC purchased a new stake in Johnson & Johnson in the 1st quarter worth approximately $32,000. Ruedi Wealth Management Inc. bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $42,000. Finally, Kepos Capital LP bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $45,000. Hedge funds and other institutional investors own 68.40% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the transaction, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now owns 87,747 shares in the company, valued at $15,092,484. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on JNJ shares. Wells Fargo & Company reduced their price objective on Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating for the company in a research report on Thursday, August 31st. Citigroup began coverage on Johnson & Johnson in a research report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 price target for the company. Atlantic Securities upped their price objective on Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research note on Friday, August 4th. TheStreet raised Johnson & Johnson from a “c+” rating to a “b+” rating in a research note on Monday, August 21st. Finally, JPMorgan Chase & Co. raised their price objective on Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. Nine analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $170.65.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $163.99 on Thursday. The stock has a 50-day moving average of $166.10 and a two-hundred day moving average of $161.64. Johnson & Johnson has a one year low of $150.11 and a one year high of $181.04. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. The stock has a market cap of $426.20 billion, a P/E ratio of 33.20, a P/E/G ratio of 3.47 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The company had revenue of $25.53 billion during the quarter, compared to analysts’ expectations of $24.63 billion. During the same quarter in the previous year, the firm posted $2.59 EPS. The firm’s revenue was up 6.3% compared to the same quarter last year. As a group, research analysts predict that Johnson & Johnson will post 10.03 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were paid a dividend of $1.19 per share. The ex-dividend date was Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.90%. Johnson & Johnson’s payout ratio is currently 96.36%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.